Procedure Guide


Indications (AHA Guidelines)

  • LKH 6-16 hrs meeting DAWN/DEFUSE-3 criteria (LOE I)

    • DEFUSE-3: NIHSS  >=6, RAPID core <70 mL, mismatch ratio >1.8 and volume >15 mL

  • Consider for LKH 16-24 hrs meeting DAWN criteria (LOE IIa)

  • Consider for M2, M3, ACA, and posterior circulation (LOE IIb)

  • Consider for extended criteria, e.g., mRS >1, NIHSS <6, ASPECTS <6 (LOE IIb)


Contraindications

Generally, the opposite of above including onset of symptoms >24 hrs ago, large core infarct due to risk of hemorrhagic conversation, small vessel occlusion or unfavorable anatomy.


Efficacy and alternatives

  • Generally, endovascular intervention is superior to best supportive medical therapy in appropriately selected patients regardless of whether they were eligible for tPA with number needed to treat of 2-3 across trials.

  • HERMES meta-analysis of major trials: TICI 2b/3 in 71% of patients with modern devices with 67% achieving a mRS of 0-2.

  • Aspiration thrombectomy is faster (~11 min) and cheaper (~$4500-5000) relative to stent-retriever with similar TICI outcomes in COMPASS, ADAPT FAST, ASTER, and PROMISE trials

  • Thrombectomy alone with Solitaire stent-retrievers non-inferior to thrombectomy + tPA (0.9 mg/kg) in SWIFT DIRECT trial, but mRS 0-2 in 57 v 65%, reperfusion in 91 vs 96%, and ICH in 2 vs 3%

  • No difference in 90d neurologic outcomes if patient in rural area sent to nearly stroke center vs thrombectomy capable referral center in RACECAT trial

  • SELECT2 RCT: medical care vs thrombectomy for major stroke (ICA or M1), all cause mortality 38.4 v 41.5%, symptomatic ICH 0.6% v 1.1%

  • ANGEL-ASPECT RCT: medical care vs thrombectomy for major stroke (ICA or M1), mRS score 0-2 30.0% v 11.6%, symptomatic ICH 6.1% v 2.7%


Pre-procedure care

  • NIHSS assessment (0-42): >=9 in 0-3 hrs of symptom onset or >7 3-6 hrs is suggestive of a large vessel occlusion (LVO)

    • Mild impairment (<5), moderate (5-14), severe (15-24), very severe (>25)

  • Can attempt to localize based on symptoms and ask about handedness 

  • Non-contrast head CT with ASPECTS

    • <=7 associated with worse functional outcomes at 3 mo and symptomatic hemorrhage

    • Guidelines recommend ASPECTS >=6 for intervention

  • CTA head and neck vs CT perfusion, both likely sufficient but CTP can provide additional valuable information re mismatch and infarct core.

    • Infarct core: elevated Tmax (>6s) and low CBF (<30%)

    • Pneumbra: elevated Tmax (>6s) volume - infarct core

    • Mean transit time (MTT) = CBV/CBF

    • Good for thrombectomy = ischemic core <70mL, mismatch ratio >1.8, mismatch volume >15mL

  • IV tPA or TNK if candidate

    • TNK (0.25 mg/kg) + thrombectomy superior to tPA (0.9 mg/kg) + thrombectomy in terms of more recanalizations, cost (cheaper by ~$2400), and single bolus rather than bolus + drip in EXTEND-IA TNK trial

    • Absolute contraindications: head trauma/surgery/stroke in last 3 mo, history of intracranial bleed/cancer/AVM/aneurysm, BP>185/110, Plts<100K, Heparin w/in 48hrs, Warfarin + INR >1.7, active internal bleed

    • Relative contraindications: seizure at onset, surgery within 2wks, GI/GU bleed within 3wks, pregnant


procedure

  • Obtain access, often CFA with alternatives including radial and direct carotid access.

    • If CFA access with tortuous iliacs, consider longer sheath

    • Radial limited to 5-6 Fr sheath

    • Direct carotid access, often short 6 Fr sheath. Should be closest to clavicle possible. Suture sheath in place and consider GA to avoid dislodgement. Can use Y-adaptor if plan for multiple exchanges.

  • Select the ICA with 5 Fr catheter (e.g. Vert) and perform cerebral angiography in AP and lateral projections.

  • Perform thrombectomy - many techniques with many variations

    • Most techniques are slight variation on similar principles and tools, generally a large sheath or balloon guide catheter into the parent vessel (e.g. cervical ICA), aspiration catheter, microwire, microcatheter, +/- stent-retriever device

      • Some advocate for trying aspiration alone first since faster and cheaper (ADAPT technique) with stent-retriever based techniques as back up

      • If using stent-retriever, retrieval force directly related to degree of integration via proper positioning, pushing out closed cell stents, allow 5-7 minutes for integration

      • Harder to retrieve with longer dwell time, multiple passes, and high fibrin content

      • Higher risk of thrombus shearing with small aspiration catheter

      • Distal to M2 and PCA can be challenging with ischemia risk from catheter being occlusive and shearing small perforators, particularly distal superior MCA branches along frontal operculum

    • ADAPT FAST technique

      • Place balloon guide catheter or large sheath into parent vessel

      • Advance triaxial system but AVOID distal passage

      • Remove microwire and microcatheter

      • Slight negative pressure on aspiration catheter with 50 mL syringe until absence of backflow

      • Inflate BGC if using, advance aspiration catheter slight forward and then slowly withdraw under forceful negative aspiration

      • E.g. default Einstein approach: 8F groin sheath, 4F Berenstein cath and glidewire advantage, Neuro Max sheath, Penumbra 68, Penumbra 3 max, Marksman cath, fathom 0.016 vs synchro 2 0.014

    • Balloon Guide/ Stent-retriever

      • Advance balloon guide catheter (e.g., Cello, Merci, or FlowGate 2)

        • Attached RHV with side port, flush catheter, and prep balloon

        • Good to use 1 cc syringe for inflation with 50/50 contrast to not over inflate and damage the vessel

        • Attach two 60 mL syringes for negative aspiration

      • Advance microwire (e.g. synchro 2) and microcatheter (e.g. velocity) beyond clot with gentle puff to confirm

      • Advance and unsheath stent-retriever device andallow to integrate in clot 5-7 min

      • Retriever device and microcatheter as a unit into the guiding catheter under constant aspiration until good flow reversal

      • *DO NOT perform >3xs in same vessel*

    • Solumbra technique

      • Advance large sheath into cervical internal carotid

        • Neuron Max may be superior in terms of distal softness and proximal support vs Cook Shuttle, Terumo Destination, Stryker AXS)

      • Advance distal aspiration catheter, microcatheter, and microwire to clot as above and deploy stent-retriever

      • Advance aspiration catheter under suction to clot until drip rates slows in tubing

      • Remove stent-retriever and aspiration catheter as single unit into cervical sheath

    • CAPTIVE technique

      • Advance large sheath into cervical ICA followed by triaxial system as above

      • Advance stent-retriever but turn on aspiration catheter prior to deployment

      • Remove microcatheter and advance aspiration catheter until drip rate slows in tubing (holding clot “captive”)

      • Remove stent-retriever and aspiration catheter as single unit into cervical sheath

    • TRAP/ARTS technique

      • Advance balloon guide catheter into ICA

      • Advance triaxial system to clot as above and deploy stent-retriever using forward tension technique

      • Remove microcatheter and inflate balloon guide catheter balloon

      • Initiate aspiration catheter during withdrawal of retriever until there’s resistance on the retriever wire suggesting the clot is “trapped”

      • Remove stent-retriever and aspiration catheter as single unit while aspirating through the balloon guide catheter

    • SAVE technique

      • Deploy ⅔ of stent-retriever distal to clot using the active push deployment technique

      • Advance aspiration catheter to edge of clot and starting aspiration until wedged

      • Switch aspiration to guide catheter while maintaining vacuum on aspiration catheter with  a syringe

      • Remove stent-retriever and aspiration catheter as single unit while aspirating through the guide catheter

    • GUARD technique

      • Advance 6 Fr flexible large bore guide sheath (e.g. Neuro Max) into distal petrocavernous ICA

      • Adjunctive DAC aspiration and stent-retriever similar to above

  • Can give IA rt-PA <10 mg for distal fragments even after IV rt-PA. IA GPIIb/IIIa inhibitors may also be safe in a small series.

  • Refractory cases (8.7% US cohort, 14.6% Korean cohort), e.g., intracranial dissection, refractory clot, or underlying significant atherosclerotic stenosis

    • IA GPIIb/IIIa inhibitor or primary stenting likely ideal, no difference in treatment failure (NW experience)

    • Angioplasty alone tended to have worse outcomes and lead to stenting anyways

  • Completion angiography to assess thrombolysis in cerebral infarction (TICI) scale

    • Grade 0 (no perfusion), 1 (minimal perfusion), 2A (<2/3 filling of vascular territory), 2B (complete filling but delayed), 3 (complete perfusion)

  • +/- Adjunctive carotid artery stenting or PFO closure

    • PFO/ASD closure recommended for ASD or 2nd cryptogenic stroke with PFO, otherwise debated, mixed results w/ RTCs (CLOSURE 1, PC, RESPECT trials). Guidelines generally recommend medical management.

  • Obtain hemostasis (can use closure devices for carotid access)


Complications

ICH, vascular injury, distal emboli, access site complication (bleeding, infection)

E.g. SELECT2 trial had complications in 18.5% (5.6% dissection, 3.9% vessel perforation, 6.2% vasospasm)


Post-procedure care & Follow Up

  • Non-contrast CT head, ideally dual energy to rule out ICH

  • Close neurologic monitoring for complications: herniation from mass effect (peaks @ 3-4d), hemorrhagic conversation (greater risk w/ larger infarct), SIADH, depression

  • Workup for stroke etiology (below for all strokes)

    • 30% atherosclerosis, dissection, Takayasu arteritis, Giant cell arteritis, fibromuscular dysplasia, Moyamoya;

    • 20% lacunar lipohyalinosis 2/2 HTN

    • 20% cardiogenic (AFib/Flutter, rheumatic valve dx, prosthetic valve, endocarditis, atrial myxoma, papillary fibroelastoma, DVT + PFO/ASD (“paradoxical stroke”), LV aneurysm, sick sinus syndrome, DCM)

    • 12% hemorrhagic

    • Other: sickle cell disease, polycythemia vera, essential thrombocytosis, HIT, hereditary coagulopathy

  • Risk factor modification: BP and glucose control, anticoagulation if cardioembolic, otherwise aspirin (81mg) OR clopidogrel (75mg) (DAPT only beneficial for those w/out CYP2C19 LoF alleles or stenting); atorvastatin 80mg regardless of cholesterol (SPARCL trial), stop smoking, exercise; Mediterranean diet, maybe fish oil)